Last reviewed · How we verify
sofosbuvir/velpatasvir crushed
Sofosbuvir/velpatasvir is a fixed-dose combination that inhibits hepatitis C virus (HCV) NS5B polymerase and NS5A protein, blocking viral replication.
Sofosbuvir/velpatasvir is a fixed-dose combination that inhibits hepatitis C virus (HCV) NS5B polymerase and NS5A protein, blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, all genotypes.
At a glance
| Generic name | sofosbuvir/velpatasvir crushed |
|---|---|
| Sponsor | Radboud University Medical Center |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5B polymerase and NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, essential for viral replication. Velpatasvir inhibits the NS5A protein, which plays a critical role in HCV replication and assembly. Together, they provide direct-acting antiviral activity against HCV across multiple genotypes.
Approved indications
- Chronic hepatitis C virus (HCV) infection, all genotypes
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sofosbuvir/velpatasvir crushed CI brief — competitive landscape report
- sofosbuvir/velpatasvir crushed updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI